Asset profile
GSK2586184
Small molecule
Evidence outlook · program status
Discontinued (2014), on a safety finding
GSK2586184 was GlaxoSmithKline's oral JAK1 inhibitor, taken into Phase 2 in ulcerative colitis, psoriasis and systemic lupus erythematosus. The sponsor's own stop reason on the terminated UC study NCT02000453 states that GSK terminated development because of the statin drug-drug-interaction study, so the decision is programme-wide and not indication-specific; market_id is left null. status_date is the bare year 2014: the source gives no decision date, and 2014 is fixed by the record's own 2014-08-08 completion date together with the pipeline diff below. The GSK FY2013 20-F pipeline exhibit lists "2586184" three times (ulcerative colitis I, systemic lupus erythematosus II, psoriasis II) and the FY2014 exhibit lists it nowhere, which corroborates a 2014 stop. Classed safety because a drug-drug interaction liability is the stated basis. The trials below are preserved as the program's evidence history; no evidence signal is assigned to a program the sponsor has stopped.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. Pick an indication; Research unlocks the trials, endpoints, key results and grades.
Competitive landscape
63 competitors in this universe: 1 direct rival (same mechanism and indication), 9 same-class, 53 same-indication; 26 further along in development.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials |
|---|---|---|---|---|---|
| GSK2586184: this drug | Phase 2 | Small molecule | JAK1, JAK1 | ||
| Upadacitinib (Rinvoq) | Approved | Small molecule | JAK, JAK1 | ||
| Abrocitinib (Cibinqo) | Approved | Small molecule | JAK1 | ||
| Filgotinib (Jyseleca) | Phase 3 | Small molecule | JAK, JAK1 | ||
| LNK01001 | Phase 3 | Small molecule | JAK1 | ||
| LW402 | Phase 3 | Small molecule | JAK1 | ||
| VC005 | Phase 3 | Small molecule | JAK1, JAK1 | ||
| AZD4604 | Phase 2 | — | JAK1 | ||
| IN-115314 | Phase 2 | Small molecule | JAK1 | ||
| JYP0061 | Phase 2 | Small molecule | JAK1 | ||
| AZD0449 | Phase 1 | — | JAK1 | ||
| Anifrolumab | Approved | Monoclonal antibody | Type I interferon receptor, Type I interferon receptor subunit 1 (IFNAR1) | ||
| Avacopan (Tavneos) | Approved | Small molecule | Complement C5a receptor 1 (C5aR1/CD88) | ||
| Belimumab (GSK1550188) | Approved | Monoclonal antibody | BAFF / BLyS (B-lymphocyte stimulator), BAFF (BLyS) | ||
| Deucravacitinib (Sotyktu) | Approved | Small molecule | TYK2 | ||
| Repository Corticotropin (Acthar Gel) | Approved | Peptide | Melanocortin receptors (primarily MC2R on the adrenal cortex), Melanocortin 2 receptor (MC2R) (agonist) |
…and 48 more. Research shows the complete landscape.
Unlock the full comparison
Research adds each competitor's evidence grade and sourced trial results, aligned per race, so you can see who actually has the data.
Upcoming events
No upcoming readouts on record for this asset.
All registered studies
Every ClinicalTrials.gov study of this drug's own program, grouped by indication and phase. Research unlocks the studies themselves: titles, statuses, dates and featured-trial cross-links.